Literature DB >> 32047231

Tumour infiltrating lymphocyte status is superior to histological grade, DNA mismatch repair and BRAF mutation for prognosis of colorectal adenocarcinomas with mucinous differentiation.

David S Williams1,2,3, Dmitri Mouradov4,5, Marsali R Newman1, Elham Amini6, David K Nickless7, Catherine G Fang2, Michelle Palmieri4,5, Anuratha Sakthianandeswaren4,5, Shan Li4, Robyn L Ward8,9, Nicholas J Hawkins10,11, Iain Skinner12, Ian Jones13, Peter Gibbs4,5,14,15, Oliver M Sieber16,17,18,19.   

Abstract

Mucinous colorectal adenocarcinoma (CRC) is conventionally defined by extracellular mucin comprising >50% of the tumour area, while tumours with ≤50% mucin are designated as having a mucinous component. However, these definitions are largely arbitrary and comparisons of clinico-molecular features and outcomes by proportion of mucinous component are limited. A cohort of 1643 patients with stage II/III cancer was examined for tumour mucinous component, DNA mismatch repair (MMR) status, BRAF mutation and tumour infiltrating lymphocytes (TILs). Tumours with ≤50% mucinous component exhibited similar characteristics as mucinous tumours, including association with female gender, proximal location, high grade, TIL-high, defective MMR (dMMR) and BRAF mutation. Proportion of mucinous component did not stratify disease-free survival (DFS). In univariate analysis dMMR status, but not histological grade, stratified survival for mucinous and mucinous component tumours; however, in multivariate analysis dMMR status was not an independent predictor. BRAF mutation prognostic value depended on mucinous differentiation and MMR status, with poor prognosis limited to non-mucinous pMMR tumours (HR 2.61, 95% CI 1.69-4.03; p < 0.001). TIL status was a strong independent predictor of DFS in mucinous/mucinous component tumours (HR 0.40, 95% CI 0.23-0.67; p < 0.001), and a superior predictor of prognosis compared with histological grade, MMR and BRAF mutation. Mucinous component and mucinous stage II/III CRCs exhibit clinico-molecular resemblances, with histological grade and BRAF mutation lacking prognostic value. Prognosis for these tumours was instead strongly associated with TIL status, with the most favourable outcomes in TIL-high dMMR tumours, whilst TIL-low tumours had poor outcomes irrespective of MMR status.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32047231     DOI: 10.1038/s41379-020-0496-1

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  46 in total

1.  Clinicopathological characteristics and prognostic factors of advanced colorectal mucinous adenocarcinoma.

Authors:  Tomohiro Yamaguchi; Hirokazu Taniguchi; Shin Fujita; Shigeki Sekine; Seiichiro Yamamoto; Takayuki Akasu; Ryoji Kushima; Tohru Tani; Yoshihiro Moriya; Tadakazu Shimoda
Journal:  Histopathology       Date:  2012-03-27       Impact factor: 5.087

2.  Clinicopathology and outcomes for mucinous and signet ring colorectal adenocarcinoma: analysis from the National Cancer Data Base.

Authors:  John R Hyngstrom; Chung-Yuan Hu; Yan Xing; Y Nancy You; Barry W Feig; John M Skibber; Miguel A Rodriguez-Bigas; Janice N Cormier; George J Chang
Journal:  Ann Surg Oncol       Date:  2012-04-04       Impact factor: 5.344

3.  Mucinous differentiation in colorectal cancer--indicator of poor prognosis?

Authors:  Cord Langner; Lars Harbaum; Marion J Pollheimer; Peter Kornprat; Richard A Lindtner; Andrea Schlemmer; Michael Vieth; Peter Rehak
Journal:  Histopathology       Date:  2012-02-20       Impact factor: 5.087

4.  Prognosis of mucinous histology for patients with radically resected stage II and III colon cancer.

Authors:  V Catalano; F Loupakis; F Graziano; R Bisonni; U Torresi; B Vincenzi; D Mari; P Giordani; P Alessandroni; L Salvatore; L Fornaro; D Santini; A M Baldelli; D Rossi; L Giustini; R R Silva; A Falcone; S D'Emidio; M Rocchi; S Luzi Fedeli
Journal:  Ann Oncol       Date:  2011-04-29       Impact factor: 32.976

5.  Clinical implications of mucinous components correlated with microsatellite instability in patients with colorectal cancer.

Authors:  Y S Yoon; J Kim; S-M Hong; J L Lee; C W Kim; I J Park; S-B Lim; C S Yu; J C Kim
Journal:  Colorectal Dis       Date:  2015-08       Impact factor: 3.788

6.  BRAF mutation, CpG island methylator phenotype and microsatellite instability occur more frequently and concordantly in mucinous than non-mucinous colorectal cancer.

Authors:  Hirofumi Tanaka; Guoren Deng; Koji Matsuzaki; Sanjay Kakar; Grace E Kim; Soichiro Miura; Marvin H Sleisenger; Young S Kim
Journal:  Int J Cancer       Date:  2006-06-01       Impact factor: 7.396

7.  Phenotype of microsatellite unstable colorectal carcinomas: Well-differentiated and focally mucinous tumors and the absence of dirty necrosis correlate with microsatellite instability.

Authors:  Joel K Greenson; Joseph D Bonner; Ofer Ben-Yzhak; Hector I Cohen; Ines Miselevich; Murray B Resnick; Philippe Trougouboff; Lynn D Tomsho; Evelyn Kim; Marcelo Low; Ronit Almog; Gad Rennert; Stephen B Gruber
Journal:  Am J Surg Pathol       Date:  2003-05       Impact factor: 6.394

8.  Survival after curative resection for mucinous adenocarcinoma of the colorectum.

Authors:  Yukihide Kanemitsu; Tomoyuki Kato; Takashi Hirai; Kenzo Yasui; Takeshi Morimoto; Yasuhiro Shimizu; Yasuhiro Kodera; Yoshitaka Yamamura
Journal:  Dis Colon Rectum       Date:  2003-02       Impact factor: 4.585

9.  Survival of patients diagnosed with either colorectal mucinous or non-mucinous adenocarcinoma: a population-based study in Canada.

Authors:  Lin Xie; Paul J Villeneuve; Amanda Shaw
Journal:  Int J Oncol       Date:  2009-04       Impact factor: 5.650

10.  Prognostic comparison between mucinous and nonmucinous adenocarcinoma in colorectal cancer.

Authors:  Jong Seob Park; Jung Wook Huh; Yoon Ah Park; Yong Beom Cho; Seong Hyeon Yun; Hee Cheol Kim; Woo Yong Lee; Ho-Kyung Chun
Journal:  Medicine (Baltimore)       Date:  2015-04       Impact factor: 1.889

View more
  10 in total

1.  Beyond standard data collection - the promise and potential of BRAIN (Brain tumour Registry Australia INnovation and translation registry).

Authors:  Lucy Gately; Katharine Drummond; Mark Rosenthal; Rosemary Harrup; Anthony Dowling; Andrew Gogos; Zarnie Lwin; Ian Collins; David Campbell; Elizabeth Ahern; Claire Phillips; Hui K Gan; Iwan Bennett; Oliver M Sieber; Peter Gibbs
Journal:  BMC Cancer       Date:  2022-06-02       Impact factor: 4.638

2.  Clinical significance of a microRNA signature for the identification and predicting prognosis in colorectal cancers with mucinous differentiation.

Authors:  Juan Ruiz-Bañobre; Roshni Roy; Miren Alustiza Fernández; Óscar Murcia; Rodrigo Jover; Miguel Pera; Francesc Balaguer; Rafael López-López; Ajay Goel
Journal:  Carcinogenesis       Date:  2020-11-13       Impact factor: 4.944

Review 3.  Study and analysis of antitumor resistance mechanism of PD1/PD-L1 immune checkpoint blocker.

Authors:  Zhengyi Wang; Xiaoying Wu
Journal:  Cancer Med       Date:  2020-09-02       Impact factor: 4.452

4.  Molecular profiling of the intestinal mucosa and immune cells of the colon by multi-parametric histological techniques.

Authors:  Łukasz Zadka; Karolina Chrabaszcz; Igor Buzalewicz; Ewelina Wiercigroch; Natalia Glatzel-Plucińska; Łukasz Szleszkowski; Agnieszka Gomułkiewicz; Aleksandra Piotrowska; Krzysztof Kurnol; Piotr Dzięgiel; Tomasz Jurek; Kamilla Malek
Journal:  Sci Rep       Date:  2021-05-28       Impact factor: 4.379

5.  CMTM6 expression in M2 macrophages is a potential predictor of PD-1/PD-L1 inhibitor response in colorectal cancer.

Authors:  Xuehui Wu; Xiaoliang Lan; Wanming Hu; Wanning Zhang; Xiangmeng Lai; Shaowan Xu; Jiaoying Li; Weihao Qiu; Wei Wang; Jianbiao Xiao; Feifei Wang; Yanqing Ding; Li Liang
Journal:  Cancer Immunol Immunother       Date:  2021-04-05       Impact factor: 6.968

6.  Comparison of Immune Response Assessment in Colon Cancer by Immunoscore (Automated Digital Pathology) and Pathologist Visual Scoring.

Authors:  Isabelle Boquet; Alboukadel Kassambara; Alfred Lui; Alicia Tanner; Marie Latil; Yoann Lovera; Fanny Arnoux; Fabienne Hermitte; Jérôme Galon; Aurelie Catteau
Journal:  Cancers (Basel)       Date:  2022-02-24       Impact factor: 6.639

Review 7.  Leveraging Comprehensive Cancer Registry Data to Enable a Broad Range of Research, Audit and Patient Support Activities.

Authors:  Belinda Lee; Lucy Gately; Sheau Wen Lok; Ben Tran; Margaret Lee; Rachel Wong; Ben Markman; Kate Dunn; Vanessa Wong; Matthew Loft; Azim Jalili; Angelyn Anton; Richard To; Miles Andrews; Peter Gibbs
Journal:  Cancers (Basel)       Date:  2022-08-26       Impact factor: 6.575

8.  Establishment and validation of a postoperative predictive model for patients with colorectal mucinous adenocarcinoma.

Authors:  Pengchao Wang; Qingyu Song; Ming Lu; Qingcheng Xia; Zijun Wang; Qinghong Zhao; Xiang Ma
Journal:  World J Surg Oncol       Date:  2022-10-03       Impact factor: 3.253

9.  Development and validation of MMR prediction model based on simplified clinicopathological features and serum tumour markers.

Authors:  Yinghao Cao; Tao Peng; Han Li; Ming Yang; Liang Wu; Zili Zhou; Xudan Zhang; Shengbo Han; Haijun Bao; Kailin Cai; Ning Zhao
Journal:  EBioMedicine       Date:  2020-10-20       Impact factor: 8.143

10.  Risk Factors for Recurrence of Radically Resected Mucinous Colorectal Adenocarcinoma.

Authors:  Qing Huang; Min-Hong Zou; Jian-Chang Wei; Ye Jiang; Zhuan-Peng Chen; Qiang Wang; Wang-Lin Li; Jie Cao
Journal:  Cancer Manag Res       Date:  2021-06-17       Impact factor: 3.989

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.